8RK.F LABIANA HEALTH S.A.EO-10
- Market cap
- EUR 40.2M
- P/E
- 13.5x
- P/B
- 7.98x
- ROE
- 50.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 8RK.F undervalued?
Graham number8RK.F trades 119.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LABIANA HEALTH S.A.EO-10 fundamental analysis
No fundamental analysis for LABIANA HEALTH S.A.EO-10 yet.
LABIANA HEALTH S.A.EO-10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina La…
Full company profileLABIANA HEALTH S.A.EO-10 financial statements
LABIANA HEALTH S.A.EO-10 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 57.0M | 57.8M | 58.5M | 66.3M | 75.2M |
| Gross Profit | 35.0M | 32.6M | 34.3M | 40.9M | 46.0M |
| Operating Income | 654K | -2.38M | -1.84M | 5.10M | 7.30M |
| EBITDA | - | -894K | 3.11M | 9.06M | 10.9M |
| Net Income | -1.78M | -8.94M | -4.42M | 253K | 2.57M |
| EPS | -0.25 | -1.24 | -0.61 | 0.04 | 0.36 |
| Balance Sheet | |||||
| Total Assets | 68.4M | 60.8M | 59.1M | 52.0M | 57.5M |
| Total Liabilities | 56.8M | 53.9M | 55.7M | 49.4M | 52.8M |
| Shareholders' Equity | 11.6M | 7.03M | 3.58M | 2.87M | 5.08M |
| Cash & Short-term Investments | 3.28M | 2.52M | 2.96M | 6.74M | 5.91M |
| Cash Flow | |||||
| Operating Cash Flow | 3.91M | 4.68M | -1.83M | 7.19M | 1.70M |
| Capital Expenditure | 4.77M | 5.45M | 2.85M | 3.05M | 4.44M |
| Free Cash Flow | -859K | -774K | -4.68M | 4.15M | -2.74M |
| Ratios | |||||
| ROE | -15.3% | -127.1% | -123.5% | 8.8% | 50.5% |
| ROA | -2.6% | -14.7% | -7.5% | 0.5% | 4.5% |
| Net Profit Margin | -3.1% | -15.5% | -7.6% | 0.4% | 3.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LABIANA HEALTH S.A.EO-10 dividends
LABIANA HEALTH S.A.EO-10 has not paid dividends in the last 5 fiscal years.
Who owns LABIANA HEALTH S.A.EO-10
- Insiders 63.07%
- Institutions 9.77%
- Public & others 27.17%
- Shares outstanding 8.49M
- Free float 2.10M
LABIANA HEALTH S.A.EO-10 company profile
- Company name
- LABIANA HEALTH S.A.EO-10
- Ticker
- 8RK.F
- ISIN
- ES0105638003
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 373
- Fiscal year end
- December
- Address
- Av. Europa, Pozuelo de Alarcón, Spain, 28023
- Phone
- 34 919 91 26 28
- Website
- labiana.com
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina Labiana brand name. In addition, it offers contract development and manufacturing services. The company was founded in 1958 and is based in Pozuelo de Alarcón, Spain.
LABIANA HEALTH S.A.EO-10 management
8- Mr. Manuel Ramos OrtegaPresident, CEO & Chairman
- Mr. Miquel Pujolriu GimenezCFO & Secretary of the Board
- Cristina Ramos RecoderDirector of Investor Relations
- Ivana NovoaHR Director
- Ms. Sandra Villagrasa ClementeExecutive Director
- Xavier Perez RamosManaging Director of Animal Division
- Dragoljub MilinkovicManaging Director of Zavod
- Suva KayaManaging Director of Zoleant